drugset / Trial / NCT03137199

Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma

NCT03137199 ↗

Phase 1 Terminated 3 enrolled Marilyn Glassberg The Marcus Foundation · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase 1 investigation will be performed to test the safety of two doses of bone marrow-derived MSCs (20,000,000 and 100,000,000) administered via peripheral intravenous infusion.

Timeline

Start
2017-06-22
Primary completion
2020-03-03
Completion
2020-04-29

Outcome

Outcome not reported

Stopped (Business): “First cohort completed. Per sponsor decision.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject hMSCs Cell therapy 2e+07 cells Intravenous
Subject hMSCs Cell therapy 1e+08 cells Intravenous

Indications